Bio-Rad Laboratories (BIO) AI Stock Analysis

• Market Cap: $7.01B
• Dividend Yield: N/A
• Average Volume (3M): 433.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: -3.92%
• EPS Growth: -202.80%
• Country: US
• Employees: 7,700
• Sector: Healthcare
• Sector Strength: 69
• Industry: Medical - Devices
• EPS (TTM): 2.90
• Shares Outstanding: 22,940,805
• 10 Day Avg. Volume: 491,555
• 30 Day Avg. Volume: 433,357
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.80
• Price to Cash Flow (P/CF): 14.50
• P/FCF Ratio: 13.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $329.75
• Price Target Upside: 35.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

Bio-Rad Laboratories faces significant challenges with profitability and revenue growth, as reflected in its financial performance and technical indicators. The stock's valuation is impacted by recent losses, and the technical analysis indicates bearish trends. The earnings call provides a cautious outlook with some positive strategic initiatives. Overall, the company needs to address these challenges to improve its stock performance.

Positive Factors

Cash Flow Improvement

The CFO is targeting a significant increase in free cash flow by improving terms with suppliers and employing lean methods to reduce inventories.

Management Strategies

New management is executing strategies to improve margins and free cash flow.

Valuation Potential

The valuation suggests potential for growth if management successfully executes its strategies and improves future earnings and cash flow projections.

Negative Factors

Operational Efficiency Issues

The company has more cash tied up in working capital than its peers, indicating inefficiencies.

Working Capital Inefficiencies

The company has more cash tied up in working capital than its peers, with inventory turns significantly down compared to pre-COVID levels.

Bio-Rad Laboratories Business Overview & Revenue Model

Company Description

Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products and solutions for the life science research and clinical diagnostics markets. The company operates in two main segments: Life Science and Clinical Diagnostics. Its core offerings include reagents, laboratory instruments, software, and consumables that are essential for scientific research, drug development, and disease diagnosis. Bio-Rad is known for its high-quality products that support advancements in healthcare and research globally.

How the Company Makes Money

Bio-Rad Laboratories generates revenue primarily through the sale of its products and services in the Life Science and Clinical Diagnostics segments. The Life Science segment offers tools and technologies that facilitate research in genomics, proteomics, cell biology, and food safety. Products in this segment include reagents, laboratory instruments, and software that researchers and scientists use in experiments and analyses. The Clinical Diagnostics segment provides a wide range of products for blood testing, diabetes monitoring, quality control, and infectious disease testing. Revenue is derived from the direct sale of these products to hospitals, laboratories, and research institutions worldwide. Additionally, Bio-Rad benefits from strategic partnerships and collaborations with academic institutions, research organizations, and other companies in the biotechnology and healthcare sectors, which further enhance its market reach and innovation capabilities.

Bio-Rad Laboratories Financial Statement Overview

Summary

Bio-Rad Laboratories shows a mixed financial performance with stable production cost management but struggles with revenue growth and profitability in recent years. The balance sheet reflects a strong equity base, while cash flow generation remains robust, albeit affected by negative income. Ongoing challenges include managing operating expenses and returning to profitability.

Income Statement

Bio-Rad Laboratories has experienced fluctuating revenue over the years, with a notable decrease in 2024 compared to previous years. The company shows negative net income in recent periods, impacting the net profit margin adversely. The gross profit margin remains relatively stable, indicating cost efficiency in production. However, the EBIT margin has declined, reflecting challenges in managing operating expenses efficiently.

Balance Sheet

The company's balance sheet shows a strong equity position with stockholders' equity consistently higher than total liabilities, leading to a healthy equity ratio. However, the debt-to-equity ratio has risen slightly, suggesting increased leverage. The return on equity has been volatile, reflecting inconsistent profitability.

Cash Flow

Bio-Rad Laboratories maintains positive operating cash flow, indicating strong cash generation capacity. The free cash flow has grown in recent years, which is a positive indicator. However, the operating cash flow to net income ratio has been significantly impacted by negative net income, highlighting potential cash flow management challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.57B	2.67B	2.80B	2.92B	2.55B
	Gross Profit
1.38B	1.43B	1.57B	1.64B	1.44B
	EBIT
269.00M	337.80M	482.62M	489.43M	410.96M
	EBITDA
-2.14B	-608.26M	-4.49B	5.63B	5.10B
	Net Income Common Stockholders
-1.84B	-637.32M	-3.63B	4.25B	3.81B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.18B	1.61B	1.80B	875.48M	996.68M
	Total Assets
9.36B	12.30B	13.50B	17.78B	12.97B
	Total Debt
174.30M	1.41B	1.20B	11.00M	14.06M
	Net Debt
174.30M	1.00B	763.97M	-459.78M	-648.15M
	Total Liabilities
2.79B	3.56B	3.89B	4.11B	3.09B
	Stockholders Equity
6.57B	8.74B	9.62B	13.67B	9.88B
Cash Flow		Free Cash Flow
266.20M	218.26M	80.29M	535.72M	476.41M
	Operating Cash Flow
455.20M	374.94M	194.45M	656.52M	575.33M
	Investing Cash Flow
-160.20M	20.21M	-1.21B	-784.44M	-60.25M
	Financing Cash Flow
-218.80M	-425.65M	973.58M	-55.43M	-523.04M

Bio-Rad Laboratories Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 242.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Neutral. The current price of 242.63 is above the 20-day moving average (MA) of 240.76, below the 50-day MA of 255.51, and below the 200-day MA of 314.14, indicating a neutral trend. The MACD of -3.36 indicates Negative momentum. The RSI at 51.37 is Neutral, neither overbought nor oversold. The STOCH value of 69.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIO.

Bio-Rad Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INSP	71 Outperform	$4.39B	85.11	8.48%	―	28.49%	―
ITGR	70 Outperform	$4.24B	57.59	4.98%	―	7.48%	-22.05%
BRKR	60 Neutral	$5.92B	51.51	7.16%	0.51%	13.56%	-73.92%
IRTC	56 Neutral	$3.38B	―	-75.27%	―	20.13%	10.05%
LIVN	54 Neutral	$2.03B	32.45	4.87%	―	8.33%	256.54%
Sector *	51 Neutral	$5.32B	3.32	-40.25%	2.90%	17.93%	2.14%
BIO	47 Neutral	$7.01B	―	-24.09%	―	-3.92%	-202.80%

Bio-Rad Laboratories Corporate Events

Bio-Rad Laboratories Updates on Sartorius Investment

Bio-Rad Laboratories has provided an update regarding its investment in Sartorius AG, which disclosed its financial results for the year ending December 31, 2024, on February 17, 2025. Sartorius AG reported sales revenue of €3,380.7 million, a gross profit of €1,524.4 million, and a net profit of €137.4 million, reflecting its financial performance and operational insights.